On March 23, nuo sincere be good at China - B (09969.HK) place is reached in harbor " the cloud strikes gong " hang out one's shingle appear on the market, become first landed harbor to make the biology medicine science and technology of place 2020, also be harbor first replace spot of financial congress hall to appear on the market with network video form ceremonial company.
Nuo sincere be good at China appear on the market first days to go against city to drive 9.4 HK dollar high, relatively issue valence to rise 5.03% . Up to distribute news dispatches, its share price goes up for 11.17% , newest market prise is 12.45 billion HK dollar.
Nuo sincere be good at China there is a star person in father -- apply one fair, ever held the post of Tsinghua vice-chancellor, currently hold the post ofpresident of west lake university, science of Tsinghua university life and medical academy dean. According to book of raise capital by floating shares, use one fair wife Zuo benevolence takes up the post of a company to carry out trustee, biology and chief inspector of clinical development strategy. Use one fair husband and wife aggregate hold Nuo sincere be good at China about 156 million share, occupy about total share is proportional after issueing 12.43% , with price of put on sale 8.95 HK dollar are calculated, its market prise is 1.27 billion yuan about.
First " the cloud strikes gong " appear on the market company
Below epidemic situation concussion, appear on the market to ceremonial company and investor also can be experienced and be shared to let cannot come to Hong Kong attend appear on the market brought joyance, harbor hands in place to announce roll out since March 23 brand-new " the cloud strikes gong " the network appears on the market ceremony, replace spot of financial congress hall to appear on the market with network video form first ceremony, nuo sincere be good at China become a home to be used in field of harbor stock market " the cloud strikes gong " adoption company.
Nuo sincere be good at China it is a biology medicine company that is in clinical phase, be worth the devoted phase of new drug research and development currently. The company still has no a product to be sold in the market up to now, amounted to 2.436 billion yuan to caustic of net loss of accumulative total of before 2019 3 quarters 2017, and continuously deficit or it is short-term inside normal.
Current, nuo sincere be good at China the group discovers and research and development await 9 kinds choose medicaments, those who aim at is the remedy that is used at treating cancer and oneself immunity disease, the reachs MCL to get used to disease new drug application that includes a kind of recrudesce to treat CLL/SLL hard already was referred grant national medicines and chemical reagents controls management board (NMPA) obtain accept await choose medicaments.
The company points out clearly in book of raise capital by floating shares, can continue to enlarge development to await anthology medicaments, seek superintendency approval, together with follow-up is rolled out await choose medicaments to need to strengthen commercialize reach a sale to work, company future still will continue to maintain deficit position for some time.
Although outstanding achievement deficit, but back uses one general concept and its star product abstruse cloth replaces the Buddhist nun (ICP-022, BTK depressor) add hold, nuo sincere be good at China next the first prize already won in 2 class market before this, this obtain 298.75 times subscribe in phase of public put on sale.
Nuo sincere be good at China Yi of Yi of starlight of father group it may be said. Nuo sincere be good at China apply by president of university of academician of the Chinese Academy of Sciences, west lake one fair with before ability CEO holds Baonuoke concurrently Cui of presiding and scientific official ceases raining or snowing loose combination establishs, its core advocate start group member also mostly science and technology of Yu Baonuo of one's previous experience, biology and strategic program are for instance advanced Ren Bin of Zhao of chief inspector, executive trustee (apply one fair spouse) ever was Baonuoke ability medicine grinds biologic chief inspector; Ming Baoceng of king of executive chief inspector of manpower resource and operation is resource of manpower of the science and technology that protect Nuo senior inspector general; Liu Ruiqin of biologic executive chief inspector ever was to protect medicine of Nuo science and technology to grind biologic senior inspector general; Chen Xiangyang of pharmaceutical chemistry vice-president ever was to protect pharmaceutical chemistry of Nuo science and technology to carry out chief inspector.
According to book of raise capital by floating shares, appear on the market after issueing, hebert Pang Kee Chan of Malaysia book person is this company the largest stockholder, hold 12.89% share; Zhao Renbin and familial hold 12.43% , for the 2nd large stockholder; Cui Ji pine and familial hold 11.38% . Although serve as those who combine father to use share of one fair not direct hold, and by its wife Zhao Ren Bin holds a scale to calculate, apply social status of one fair couple to exceed 1.27 billion yuan.
Nuo sincere be good at China another principal shareholder calls LVC entity, hold 9.66% , the old man of its backside is Lin Lijun, ever founded collect what buy rich fund and hold the position of general manager 10 years is long, founded subsequently capital of heart cereal innovation. According to exposure of book of raise capital by floating shares, lin Lijun is in 2015-2019 year had taken up the post of harbor appear on the market director of company Yun Feng finance.
Future is commercialized but period
How make make up the deficits and get surpluses commercialize a plan to become investor to Nuo sincere be good at China the thing that cares most after IPO.
On March 20, nuo sincere be good at China release announcement to say to issue a price to be 8.95 HK dollar. Match carry out result publicly to show, nuo sincere be good at China collect endowment forehead two billion two hundred and forty million four hundred thousand HK dollar. Earning money net specified number will use as the following utility: 50.0% register file and potential business to roll out with the clinical trial that is in China and United States to agree to undertaking at the same time and plan to undertake for the Buddhist nun as abstruse cloth, preparation (include sale and sale) bankroll. 25% with two when serve as a company clinical phase is awaited choose product fund; 15% await with what plan stage as 6 kinds of IND in company cop the research and development that elects medicaments and await the research and development that elects medicaments newly to reach exterior recommend fund; 10% use as etc of battalion transport fund is general company use.
Nuo sincere be good at China commercializing ready-made to come true at present. Apply one fair with Nuo sincere be good at China the agreement of exclusive strategy cooperation that signed by a definite date 3 years in August 2018, the ability of own research and development of the company is applied by structural biologist one fair learn expert Zhang Zemin to provide support with cancer gene group, during collaboration, apply one fair will be in new drug discovery the assistance that provides concerned question and guidance.
On the other hand, nuo sincere be good at China stare at Chinese market closely. Its are used at cure a variety of B cells are malign abstruse cloth replaces the core remedy of tumor and oneself immunity disease the Buddhist nun, already two basically get used to disease direction greatly appear on the market application (NDA) obtain bureau of inspect of our country medicine (CDE) accept.
Additional, nuo sincere be good at China cash reserve is abundant, company of several years grows enough future. According to the exposure in book of raise capital by floating shares, up to on September 30, 2019, nuo sincere be good at China total value of hold liquid assets is as high as 2.4 billion RMB, plus this second appear on the market the 2 billion or so HK dollar that financing acquires, enough the Nuo that prop up sincere be good at China the capital requirement in coming several years.
Current, market of Chinese tumour drug is in erupt overnight, and relevant obtain batch of medicaments onefold. As population aged the growth with cancer incidence of a disease, and cancer treatment mode reachs tumor immunity therapeutics to drive to therapeutics by target of traditional element of the travel that change cure, be like Sitesha according to notting benefit article data, dimensions of market of Chinese tumour drug will break through one billion two hundred and fifteen million seven hundred and fifty-two thousand one hundred and ninety-two dollars 2030.
